APA (7th ed.) Citation

B, L., ZH, J., G, L., Y, Y., & Y, L. (2026). Efficacy and safety of octreotide versus somatostatin therapy after CRS + HIPEC in patients with peritoneal carcinomatosis. Discover oncology, 17(1), 321. https://doi.org/10.1007/s12672-026-04420-7

Chicago Style (17th ed.) Citation

B, Li, Ji ZH, Liu G, Yu Y, and Li Y. "Efficacy and Safety of Octreotide Versus Somatostatin Therapy After CRS + HIPEC in Patients with Peritoneal Carcinomatosis." Discover Oncology 17, no. 1 (2026): 321. https://doi.org/10.1007/s12672-026-04420-7.

MLA (9th ed.) Citation

B, Li, et al. "Efficacy and Safety of Octreotide Versus Somatostatin Therapy After CRS + HIPEC in Patients with Peritoneal Carcinomatosis." Discover Oncology, vol. 17, no. 1, 2026, p. 321, https://doi.org/10.1007/s12672-026-04420-7.